New study tracks safety of heart drug mavacamten in pregnancy
NCT ID NCT05939700
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study is looking at the safety of the heart medication mavacamten when taken during pregnancy or while breastfeeding. Researchers will follow about 20 people who have taken at least one dose of mavacamten during pregnancy or breastfeeding, tracking outcomes for both the mother and baby up to one year after birth. The goal is to better understand any risks or complications, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mavacamten
What this could lead to
If this study succeeds, it could provide important safety information about using mavacamten during pregnancy and breastfeeding, helping doctors and patients make informed decisions.
What could go wrong
This is a small observational study with only 20 participants, so results may not apply to everyone. It is designed to gather data, not to test a new treatment, so no direct health benefits are expected for participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREASTFEEDING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
The Mavacamten Pregnancy Surveillance Program, PPD Inc
RECRUITINGWilmington, North Carolina, 28401-3331, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••